

OUR ELISA KITS DESIGNED FOR YOUR CLINICAL & PRE-CLINICAL APPLICATION



QUANTITATIVE

EASY-TO-USE

RELIABLE

Features & Benefits

- \checkmark Characterized epitope-mapped antibodies
- \checkmark Validated for clinical samples according to ICH and FDA guidelines
- \checkmark Human serum based calibrators & controls
- \checkmark Proprietary products in-house R&D and production
- \checkmark Personal and competent customer service

SERVICE MEASUREMENTS available





BIOMEDICA develops and produces internationally recognized high quality ELISA kits for clinical research in the field of cardiorenal diseases as well as bone and mineral disorders.

Our customers include numerous top ranking scientific institutions worldwide, well-known CROs and laboratories in the pharmaceutical industry. We are setting the standard for clinical research using serum-based calibrators and controls, thus enabling researchers to collect biologically reliable data. The provided immunoassays are fully validated. Biomedica's experienced and qualified team of professionals provides technical and scientific support.

The majority of our assays are $\boldsymbol{\zeta} \in$ marked and ready for use in IVD. The company's manufacturing processes comply with ISO 9001:2015 management system standards and conform to GMP/GLP guidelines.

For specific markers, Biomedica has become a market leader with a continuously growing portfolio. A worldwide distribution network has been established for these products as well as an analytical service, which offers customers in-house diagnostic analysis of their samples.

Analytical Testing Service

Biomedica offers a comprehensive testing service for all our proprietary ELISAs as well as assays from other brands including Luminex testing services.

As an experienced ELISA assay developer and manufacturer located in the heart of Europe, our staff contribute to every step in the making of our ELISAs, thereby gaining a unique understanding of the assays' performance.

Using our analytical customized testing service, even customers without access to a fully equipped laboratory or skilled staff are able to obtain reliable biomarker results from samples of both human and animal origin.

Advantages

 \checkmark High-quality services \checkmark Comprehensive results report

 \checkmark Experienced, trained staff \checkmark Expert sample handling



<i>NEW</i> Human Vanin-1	Key areas:	nephrology
(Urine) ELISA	Related diseases:	acute kidney injury, diabetic nephropathy, drug-induced acute kidney injury, hydronephrosis
Cat. No. BI-VAN1U	Measures: Sample type: Assay time: Sample volume: Use: References:	human Vanin-1 urine 4.5 hr 10µl / well research use only 2 (product specific)
NEW Vanin-1 Mouse/Rat ELISA	Key areas: Related diseases:	nephrology acute kidney injury, diabetic nephropathy, drug-induced acute kidney injury, hydronephrosis
Cat. No. BI-VAN1MR	Measures: Sample type: Assay time: Sample volume: Use:	mouse and rat Vanin-1 mouse and rat serum, plasma and urine 4.5 hr 5µl / well research use only
Intact FGF23 ELISA	Key areas: Related diseases:	bone and phosphate metabolism, nephrology, cardiovascular homeostasis hypophosphatemia, vitamin D disorders, autosomal dominant hypophosphatemia (ADHR), X-linked hypophosphatemia (XLH), fibrous dysplasia of the bone
Cat. No. BI-20700	Measures: Sample type: Assay time: Sample volume: Use: References:	intact FGF23 human plasma (EDTA, citrate, heparin), protocol for human serum, urine and cell culture supernatant 3.5 hr 50µl / well (€ marked - for IVD use in the EU 7 (product specific)
C-terminal FGF23 ELISA	Key areas: Related diseases:	bone and phosphate metabolism, nephrology, cardiovascular homeostasis hypophosphatemia, vitamin D disorders, autosomal dominant hypophosphatemia (ADHR), X-linked hypophosphatemia (XLH), fibrous dysplasia of the bone
Cat. No. BI-20702	Measures: Sample type: Assay time: Sample volume: Use: References:	<pre>intact and the C-terminal fragment of FGF23 human serum and plasma (EDTA, citrate, heparin) overnight assay 50µl / well (€ marked - for IVD use in the EU 32 (product specific)</pre>
Sclerostin	Key areas: Related diseases:	bone and mineral metabolism bone and vascular diseases, osteoporosis,
ELISA	Related diseases:	cancer induced bone diseases, renal disorders
Cat. No. BI-20492	Measures: Sample type: Assay time: Sample volume: Use: References:	Wnt-signalling antagonist Sclerostin (SOST) human serum and plasma (EDTA, heparin), cell culture and urine protocol overnight assay 20µl / well research use only 230+ (product specific)



Bioactive	Key areas: Related diseases:	bone and mineral metabolism bone and vascular disease, osteoporosis, cancer induced bone diseases, renal disorders
Sclerostin ELISA Cat. No. BI-20472	Measures: Sample type: Assay time: Sample volume: Use: References:	bioactive Sclerostin and Sclerostin fragments; antibody binding occurs in the LRP5/6 binding region human serum and plasma (EDTA, citrate), cell culture and urine protocol 3.5 hrs 20µl / well research use only 4 (product specific)
	Key areas:	bone and mineral metabolism
DKK-1 ELISA	Related diseases:	osteoporosis, rheumatoid arthritis, cancer induced bone diseases, vascular calcification, diabetes
Cat. No. BI-20413	Measures: Sample type: Assay time: Sample volume: Use: References:	Wnt-signalling antagonist Dickkopf-1 human serum 3.5 hrs 20µl / well (€ marked – for IVD use in the EU 150+ (product specific)
	Key areas:	bone homeostasis, tissue development and repair
Periostin ELISA	Related diseases:	osteoporosis, cancer induced bone diseases, cardiovascular diseases, hypertension, respiratory diseases
Cat. No. BI-20433	Measures: Sample type: Assay time: Sample volume: Use: References:	all known isoforms of human Periostin human serum and plasma (EDTA, citrate, heparin), cell culture and urine protocol 5.5 hrs 10µl / well research use only 16 (product specific)
	Key areas:	bone homeostasis, tissue development and repair
Periostin Mouse ELISA Cat. No. BI-20433MS	•	osteoporosis, cancer induced bone diseases, cardiovascular diseases, hypertension, respiratory diseases
	Measures: Sample type: Assay time: Sample volume: Use: References:	mouse Periostin mouse serum and plasma, cell culture supernatant protocol 4.5 hrs $\leq 5 \mu \text{l} / \text{ well}$ for pre-clinical use 3 (product specific)
Free sRANKL ELISA	Key areas: Related diseases:	bone and mineral metabolism, thermoregulation osteoporosis, diseases with locally increased resorption activity, arthritis, type 2 diabetes, cancer induced bone diseases
Cat. No. BI-20462	Measures: Sample type: Assay time: Sample volume: Use: References:	soluble, uncomplexed receptor RANKL (receptor activator of NF-κB) human serum and plasma (heparin) overnight assay 150µl / well (€ marked – for IVD use in the EU 270+ (product specific)



Osteoprotegerin (OPG) ELISA	Key areas: Related diseases:	bone and mineral metabolism osteoporosis, arthritis, diseases with locally increased resorption activity, cardiovascular disease, vascular calcification
Cat. No. BI-20403	Measures: Sample type: Assay time: Sample volume: Use: References:	monomeric and dimeric Osteoprotegerin human serum and plasma (EDTA, heparin, citrate) 5.5 hrs 20µl / well (€ marked – for IVD use in the EU 220+ (product specific)
Soluble Semaphorin 4D ELISA	Key areas: Related diseases:	bone homeostasis, immune response, cell migration, vascula- risation, neural connectivity, tumor progression osteoporosis, arthritis, type 2 diabetes, cancer related bone diseases, neurological diseases
Cat. No. BI-20405	Measures: Sample type: Assay time: Sample volume: Use: References:	soluble SEMA4D/CD100 human plasma (EDTA, citrate, heparin), cell culture protocol 4.5 hrs 10µl / well research use only 4 (product specific)
Total Soluble Neuropilin-1 ELISA	Key areas: Related diseases:	immunology, osteology, cardiology, nephrology, oncology kidney disease, cardiovascular disease, cancer
Cat. No. BI-20409	Measures: Sample type: Assay time: Sample volume: Use: References:	total soluble NRP1 human serum and plasma (EDTA, citrate, heparin), protocol for cell culture supernatant, urine, and non-human samples 4 hrs 10µl / well research use only 3 (product specific)
Endostatin ELISA	Key areas: Related diseases:	angiogenesis, cardiovascular homeostasis artherosclerosis, chronic kidney disease (CKD), ischemia, stroke, micro-vascular injury, renal fibrosis, preeclampsia
Cat. No. BI-20742	Measures: Sample type: Assay time: Sample volume: Use: References:	angiogenesis inhibitor Endostatin human serum and plasma (EDTA, citrate, heparin) 4.5 hrs 10µl / sample research use only 4 (product specific)
Endostatin Mouse/Rat ELISA	Key areas: Related diseases:	angiogenesis, cardiovascular homeostasis artherosclerosis, chronic kidney disease (CKD), ischemia, stroke, micro-vascular injury, renal fibrosis, preeclampsia
Cat. No. BI-20742MR	Measures: Sample type: Assay time: Sample volume: Use: References:	angiogenesis inhibitor Endostatin in mouse and rats mouse and rat serum and plasma (EDTA, citrate, heparin) 2.5 hrs 5µl / sample for pre-clinical use 2 (product specific)



NT-proCNP ELISA	Key areas: Related diseases:	angiogenesis, growth, skeletal development, cardiovascular homeostasis cardiovascular disease, renal disorders, sepsis, SIRS, pre- eclampsia
Cat. No. BI-20812	Measures: Sample type: Assay time: Sample volume: Use: References:	NT-proCNP (AA 24-73) human serum and plasma (EDTA, citrate, heparin), protocol for cell culture supernatant, urine, and non-human samples 4 hrs 20µl / well (€ marked – for IVD use in the EU 43 (product specific)
NT-proANP	Key areas: Related diseases:	cardiovascular homeostasis, cardiotoxicity in preclinical studies cardiovascular disease, heart failure, transplants, sepsis
ELISA Cat. No. BI-20892	Measures: Sample type: Assay time: Sample volume: Use: References:	NT-proANP (AA 1-98) human, rat, mouse, cat and dog serum and plasma (EDTA, heparin), cell culture supernatant, urine 3.5 hrs 10µl / well ((marked – for IVD use in the EU 149 (product specific; 14 references: CV safety biomarker in rats)
NT-proBNP ELISA	Key areas: Related diseases:	cardiovascular and renal homeostasis, regulation of fatty acid metabolism obesity, diabetes, renal failure, cardiac impairment, acute myocardial infarction, secondary hypertension
Cat. No. SK-1204	Measures: Sample type: Assay time: Sample volume: Use: References:	NT-proBNP (AA 1-76) human serum and plasma (EDTA) 3.5 hrs 50µl / well (€ marked – for IVD use in the EU 65 (product specific)
BNP fragment ELISA	Key areas: Related diseases:	cardiovascular homeostasis, renal homeostasis, regulation of fatty acid metabolism obesity, diabetes, renal failure, cardiac impairment, acute myocardial infarction, secondary hypertension
Cat. No. BI-20852W	Measures: Sample type: Assay time: Sample volume: Use: References:	NT-proBNP (AA 1-76) and all fragments containing AA 8-29 of NT-proBNP human serum and plasma (EDTA, citrate, heparin) overnight assay 30µl / well research use only 54 (product specific)
Big Endothelin-1	Key areas: Related diseases:	regulation of vascular homeostasis arterial hypertension and cardiovascular disorders,
ELISA Cat. No. BI-20082H	Measures: Sample type: Assay time: Sample volume: Use: References:	cardiac hypertension and cardiovascular alsoraers, cardiac hypertrophy, cerebral vasospasm Big Endothelin-1 (AA 1-38) human serum and plasma (EDTA, citrate, heparin) 5.5 hrs 50µl / well (c marked – for IVD use in the EU 72 (product specific)



NEW Angiopoietin-2 ELISA Cat. No. BI-ANG2	Measures: Sample type: Assay time: Sample volume: Use: References:	vascularisation, angiogenesis, inflammation, micro-vascular injury, renal fibrosis, tumor progression cardiovascular diseases, chronic kidney disease, autoimmune disease, cancer human Angiopoietin-2 human serum and plasma (EDTA, citrate, heparin) 3.5 hrs 20µl / well research use only 1 (product specific)
NEW Angiopoetin-2 Mouse/Rat ELISA Cat. No. BI-ANG2MR	Key areas: Related diseases: Measures: Sample type: Assay time: Sample volume: Use:	vascularisation, angiogenesis, inflammation, micro-vascular injury, renal fibrosis, tumor progression cardiovascular disease, chronic kidney disease, autoimmune disease, cancer mouse and rat Angiopoietin-2 mouse and rat serum and plasma 5.5 hrs 5µl / well research use only
NEW IL-6 ELISA Cat. No. BI-IL6	Key areas: Related diseases: Measures: Sample type: Assay time: Sample volume: Use:	inflammation, cancer, cardiology, nephrology, bone metabolism sepsis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, Casteleman's disease, metabolic syndrome, Covid-19 human IL-6 serum, plasma (EDTA, heparin, citrate), cc supernatant, urine 4.5 hrs 100µl / well research use only
NEW VEGF ELISA Cat. No. BI-VEGF	Key areas: Related diseases: Measures: Sample type: Assay time: Sample volume: Use:	cancer, angiogenesis, inflammation, cardiology, bone metabolism rheumatoid arthritis, psoriasis, psoriatic arthritis, diabetes and diabetic kidney disease, diabetic retinopathy, obesity human VEGF (all circulating isoforms incl. VEGF165b) serum, plasma (EDTA, heparin), cc supernatant, urine 4.5 hrs 10μl / well research use only
OxyStat Assay Cat. No. BI-5007	Key areas: Related diseases: Measures: Sample type: Assay time: Sample volume: Use: References:	oxidative stress, cardiology cardiovascular diseases biological peroxides human serum, EDTA plasma, biological fluids 15 min 10μl / well ζ€ marked – for IVD use in the EU 51 (product specific)

MDA-oxLDL ELISA	Key areas: Related diseases:	oxidative stress, cardiology cardiovascular diseases
Cat. No. BI-20022	Measures: Sample type: Assay time: Sample volume: Use: References:	malondialdehyde (MDA)-modified ApoB LDL human serum and plasma (EDTA, citrate, heparin) 3.5 hrs 20µl / well research use only 26 (product specific)
oLAB ELISA	Key areas:	oxidative stress, cardiology
(Anti oxidized LDL	Related diseases:	cardiovascular diseases
autoantibodies) Cat. No. BI-20032	Measures: Sample type: Assay time: Sample volume: Use: References:	autoantibodies to oxidized human low density lipoprotein (LDL) human serum 2 hrs 20μl / well (€ marked – for IVD use in the EU 68 (product specific)







PL-202105

BIOMEDICA Medizinprodukte GmbH

Divischgasse 4 · 1210 Vienna · Austria · EUROPE · www.bmgrp.com T +43 1 291 07 45 · F +43 1 291 07 6389 · info@bmgrp.com